175 related articles for article (PubMed ID: 8581387)
1. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu.
Valone FH; Kaufman PA; Guyre PM; Lewis LD; Memoli V; Ernstoff MS; Wells W; Barth R; Deo Y; Fisher J
J Hematother; 1995 Oct; 4(5):471-5. PubMed ID: 8581387
[TBL] [Abstract][Full Text] [Related]
2. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
[TBL] [Abstract][Full Text] [Related]
3. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.
Valone FH; Kaufman PA; Guyre PM; Lewis LD; Memoli V; Deo Y; Graziano R; Fisher JL; Meyer L; Mrozek-Orlowski M
J Clin Oncol; 1995 Sep; 13(9):2281-92. PubMed ID: 7545221
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner LM; Clark JI; Ring DB; Alpaugh RK
J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
6. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo.
Wallace PK; Kaufman PA; Lewis LD; Keler T; Givan AL; Fisher JL; Waugh MG; Wahner AE; Guyre PM; Fanger MW; Ernstoff MS
J Immunol Methods; 2001 Feb; 248(1-2):167-82. PubMed ID: 11223077
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu.
Lewis LD; Cole BF; Wallace PK; Fisher JL; Waugh M; Guyre PM; Fanger MW; Curnow RT; Kaufman PA; Ernstoff MS
J Immunol Methods; 2001 Feb; 248(1-2):149-65. PubMed ID: 11223076
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.
Repp R; van Ojik HH; Valerius T; Groenewegen G; Wieland G; Oetzel C; Stockmeyer B; Becker W; Eisenhut M; Steininger H; Deo YM; Blijham GH; Kalden JR; van de Winkel JG; Gramatzki M
Br J Cancer; 2003 Dec; 89(12):2234-43. PubMed ID: 14676800
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with CD64-directed immunotherapy. An overview.
Curnow RT
Cancer Immunol Immunother; 1997; 45(3-4):210-5. PubMed ID: 9435876
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu.
Pullarkat V; Deo Y; Link J; Spears L; Marty V; Curnow R; Groshen S; Gee C; Weber JS
Cancer Immunol Immunother; 1999 Apr; 48(1):9-21. PubMed ID: 10235484
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer.
van Ojik HH; Repp R; Groenewegen G; Valerius T; van de Winkel JG
Cancer Immunol Immunother; 1997; 45(3-4):207-9. PubMed ID: 9435875
[No Abstract] [Full Text] [Related]
15. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
16. Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu.
Schwaab T; Lewis LD; Cole BF; Deo Y; Fanger MW; Wallace P; Guyre PM; Kaufman PA; Heaney JA; Schned AR; Harris RD; Ernstoff MS
J Immunother; 2001; 24(1):79-87. PubMed ID: 11211151
[TBL] [Abstract][Full Text] [Related]
17. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.
Pegram MD; Konecny G; Slamon DJ
Cancer Treat Res; 2000; 103():57-75. PubMed ID: 10948442
[No Abstract] [Full Text] [Related]
18. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
Clark JI; Alpaugh RK; von Mehren M; Schultz J; Gralow JR; Cheever MA; Ring DB; Weiner LM
Cancer Immunol Immunother; 1997 Jul; 44(5):265-72. PubMed ID: 9247561
[TBL] [Abstract][Full Text] [Related]
19. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
[TBL] [Abstract][Full Text] [Related]
20. Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer.
Dillman RO
Cancer Biother Radiopharm; 1999 Feb; 14(1):5-10. PubMed ID: 10850281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
